Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinctive p53 and mdm2 Immunohistochemical Expression Profiles Suggest Different Pathogenetic Pathways in Poorly Differentiated Endometrial Carcinoma

1 Apr 1998

Abstract excerpt

Endometrial serous carcinoma (ESC) and FIGO (International Federation of Gynecology and Obstetrics) grade 3 endometrioid adenocarcinoma (EC) are high-grade endometrial tumors that have different clinical and morphologic attributes. Alteration of p53 tumor suppressor protein function has been implicated in the pathogenesis of both tumors, although the mechanisms may differ. We sought to investigate this difference...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial and Cervical Cancer Treatments
Share to MicroRNA in disease regulation
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 9553809
DOI: 10.1097/00004347-199804000-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinctive p53 and mdm2 Immunohistochemical Expression Profiles Suggest Different Pathogenetic Pathways in Poorly Differentiated Endometrial CarcinomaPMID 9553809Read ↗

Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.Semantic proximity Read ↗

Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.Semantic proximity Read ↗

p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.Semantic proximity Read ↗

Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.Semantic proximity Read ↗

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.Semantic proximity Read ↗

Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.Semantic proximity Read ↗

p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.Semantic proximity Read ↗

Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.Semantic proximity Read ↗

The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.Semantic proximity Read ↗

p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?Semantic proximity Read ↗

p53 overexpression as a prognostic indicator in endometrial carcinoma.Semantic proximity Read ↗

High Expression of p62 Protein Is Associated with Poor Prognosis and Aggressive Phenotypes in Endometrial Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.